			·	Sheet i o
PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 1767.2011-000		PLICATION NO. /743,557	
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Khalid K. Sadozai FILING DATE December 22,		22, 2003	
September 23, 2004 SEP 3 0 2004 (Use several sheets if necessary)	EXAMINER Not yet assigned	CONF 5063	IRMATION NO.	GROUP 1614

BADE	MARKS	F	OREIGN PATENT D	OCUMENTS	_	
	 	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANS YES	LATION NO
/C.B./	AN3	WO 02/09792 A1	02/07/2002	Anika Therapeutics, Inc.		
C.B./	AO3	WO 94/02517	02/03/1994	Anika Research, Inc.		
/C.B./	AP3	WO 92/20349	11/26/1992	Genzyme Corporation		
/C.B./	AQ3	EP 0 416 250 A2	03/13/1991	The Research Foundation of State University of New York		

PTO-1449 REPRODUCED			PLICATION NO. /743,557	
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Khalid K. Sadozai FILING DATE December 2		22, 2003	
September 23, 2004 (Use several sheets if necessary)	EXAMINER Not yet assigned	CONFI 5063	RMATION NO.	GROUP 1614

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
/C.B./	AU	Chen, J., et al., "Polysacccharide Hydrogels for Protein Drug Delivery," Carbohydrate Polymers 28 (1995) 69-76.

PTO-1449 REPRODUCED	
INFORMATION DISCLOS IN AN APPLICA	URE ATATION TO
June 18, 200	4 JUN 2-1 2004 (S)
(Use several sheets if n	ccessing)
	FRADEN

_					Sheet 1 of
	ATTORNEY DOCKET NO. 1767.2011-000			LICATION NO. 743,557	
\	FIRST NAMED INVENTOR Khalid K. Sadozai			FILING DATE December 2	22, 2003
<i> </i>	EXAMINER Not yet assigned		NFI 63	RMATION NO.	GROUP 1614

RECK No. NAME OF PATENTEE OR APPLICANT			II.S.	. PATENT DOCUMENTS	
C_B AB	INER INI-		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	
C.B. AC A,582,640 O4-15-1986 Smestad, et al.	/C.B./	AA	3,949,073	04-06-1976	Daniels, et al.
C.B. AC	/C.B./	AB	4,424,208	01-03-1984	Wallace, et al.
C.B. AE 4,851,521 07-25-1989 della Valle, et al. C.B. AF 4,937,270 06-26-1990 Hamilton, et al. C.B. AG 4,957,744 09-18-1990 della Valle, et al. C.B. AH 5,128,326 07-07-1992 Balazs, et al. C.B. AI 5,143,724 09-01-1992 Leshchiner, et al. C.B. AJ 5,246,698 09-21-1993 Leshchiner, et al. C.B. AK 5,258,028 11-02-1993 Ersek, et al. C.B. AA2 5,306,500 04-26-1994 Rhee, et al. C.B. AB2 5,336,767 08-09-1994 della Valle, et al. C.B. AC2 5,399,351 03-21-1995 Leshchiner, et al. C.B. AD2 5,523,291 06-04-1996 Janzen, et al. C.B. AE2 5,633,001 05-27-1997 Agerup C.B. AF2 5,672,301 09-30-1997 Orly, et al. C.B. AI2 5,827,937 10-27-1998 Lawin, et al. C.B. AI2 6,039,970 03-21-2000 Callegaro, et al. C.B. AI2 6,066,340 05-23-2000 Callegaro, et al. C.B. AA3 6,251,876 B1 06-26-2001 Bellini, et al. C.B. AB3 6,277,392 B1 08-21-2001 Klein C.B. AB3 6,277,392 B1 08-21-2001 Spiro, et al. C.B. AB3 6,277,392 B1 08-21-2001 Spiro, et al. C.B. AB3 6,277,392 B1 08-21-2001 Spiro, et al. C.B. AB3 6,288,043 B1 09-11-2001 Spiro, et al. C.B. AB3 6,288,043 B1 O9-11-2001 Spiro, et al. C.B. AB3 6,288,043 B1 O9-11-2001 Spiro, et al. C.B. AB3 6,288,043 B1 O9-11-2001 Spiro, et al. C.B. AB3 6,277,392 B1 O9-11-2001 Spiro, et al. C.B. AB3 6,277,392 B1 O9-11-2001 Spiro, et al. C.B. AB3 6,288,043 B1 O9-11-2001 Spiro, et al. C.B. AB4 C.B. AB4			4,582,640	04-15-1986	Smestad, et al.
C.B. AF	C.B./	AD	4,803,075	02-07-1989	Wallace, et al.
C.B. AG 4,957,744 09-18-1990 della Valle, et al. C.B. AH 5,128,326 07-07-1992 Leshchiner, et al. C.B. AI 5,143,724 09-01-1992 Leshchiner, et al. C.B. AJ 5,246,698 09-21-1993 Leshchiner, et al. C.B. AK 5,258,028 11-02-1993 Ersek, et al. C.B. AA2 5,306,500 04-26-1994 Rhee, et al. C.B. AB2 5,336,767 08-09-1994 della Valle, et al. C.B. AC2 5,399,351 03-21-1995 Leshchiner, et al. C.B. AC2 5,53,291 06-04-1996 Janzen, et al. C.B. AE2 5,633,001 05-27-1997 Agerup C.B. AF2 5,672,301 09-30-1997 Orly, et al. C.B. AG2 5,792,478 08-11-1998 Lawin, et al. C.B. AH2 5,827,937 10-27-1998 Agerup C.B. AH2 5,827,937 10-27-1998 Agerup C.B. AI2 6,039,970 03-21-2000 Callegaro, et al. C.B. AK2 6,231,613 B1 05-15-2001 Greff, et al. C.B. AK3 6,251,876 B1 06-26-2001 Bellini, et al. C.B. AK3 6,277,392 B1 08-21-2001 Klein C.B. AC3 6,288,043 B1 09-11-2001 Spiro, et al. C.B. AC3 6,288,043 B1 09-11-2001 Spiro, et al. C.B. AC3 6,288,043 B1 09-11-2001 Spiro, et al. C.B. AC3 5,288,043 B1 09-11-2001 Spiro, et al. C.B. AC3 6,288,043 B1 09-11-2001 Spiro, et al. C.B. AC3 C.B. AC3 C.B. AC3 C.B. AC4 C.B.	/C.B./	AE	4,851,521	07-25-1989	della Valle, et al.
C.B. AH 5,128,326 07-07-1992 Leshchiner, et al. C.B. AJ 5,143,724 09-01-1992 Leshchiner, et al. C.B. AJ 5,246,698 09-21-1993 Leshchiner, et al. C.B. AK 5,258,028 11-02-1993 Ersek, et al. C.B. AA2 5,306,500 04-26-1994 Rhee, et al. C.B. AB2 5,336,767 08-09-1994 della Valle, et al. C.B. AC2 5,399,351 03-21-1995 Leshchiner, et al. C.B. AD2 5,523,291 06-04-1996 Janzen, et al. C.B. AE2 5,633,001 05-27-1997 Agerup C.B. AF2 5,672,301 09-30-1997 Orly, et al. C.B. AG2 5,792,478 08-11-1998 Lawin, et al. C.B. AH2 5,827,937 10-27-1998 Agerup C.B. AH2 5,827,937 10-27-1998 Agerup C.B. AH2 6,039,970 03-21-2000 Callegaro, et al. C.B. AH2 6,036,340 05-23-2000 Callegaro, et al. C.B. AK2 6,231,613 B1 05-15-2001 Greff, et al. C.B. AB3 6,277,392 B1 08-21-2001 Klein C.B. AB3 6,277,392 B1 08-21-2001 Spiro, et al. C.B. AC3 6,288,043 B1 09-11-2001 Spiro, et al. C.B. AC3 6,288,043 B1 O9-11-2001 Spiro, et al. C.B. AC3 C	/C.B./	AF	4,937,270	06-26-1990	Hamilton, et al.
C.B./. AI 5,143,724 09-01-1992 Leshchiner, et al. /C.B./. AJ 5,246,698 09-21-1993 Leshchiner, et al. /C.B./. AK 5,258,028 11-02-1993 Ersek, et al. /C.B./. AA2 5,306,500 04-26-1994 Rhee, et al. /C.B. AB2 5,336,767 08-09-1994 della Valle, et al. /C.B. AC2 5,399,351 03-21-1995 Leshchiner, et al. /C.B./. AD2 5,523,291 06-04-1996 Janzen, et al. /C.B./. AE2 5,633,001 05-27-1997 Agerup /C.B./. AF2 5,672,301 09-30-1997 Orly, et al. /C.B./. AG2 5,792,478 08-11-1998 Lawin, et al. /C.B./. AH2 5,827,937 10-27-1998 Agerup /C.B./. AH2 6,039,970 03-21-2000 Callegaro, et al. /C.B./. AN2 6,231,613 B1 05-15-2001 Greff, et al. /C.B./. AN3 6,251,876 B1 06-26-2001 Bellini, et al. /C.B./. AN3 6,227,392 B1 08-21-2001 Klein /C.B./. AC3 6,288,043 B1 09-11-2001 Spiro, et al.	/C.B./	AG	4,957,744	09-18-1990	della Valle, et al.
/C.B./ AJ 5,246,698 09-21-1993 Leshchiner, et al. /C.B./ AK 5,258,028 11-02-1993 Ersek, et al. /C.B.// AA2 5,306,500 04-26-1994 Rhee, et al. /C.B. AB2 5,336,767 08-09-1994 della Valle, et al. /C.B.// AC2 5,399,351 03-21-1995 Leshchiner, et al. /C.B.// AD2 5,523,291 06-04-1996 Janzen, et al. /C.B.// AE2 5,633,001 05-27-1997 Agerup /C.B.// AF2 5,672,301 09-30-1997 Orly, et al. /C.B.// AG2 5,792,478 08-11-1998 Lawin, et al. /C.B.// AH2 5,827,937 10-27-1998 Agerup /C.B.// AH2 6,039,970 03-21-2000 Callegaro, et al. /C.B.// AH2 6,066,340 05-23-2000 Callegaro, et al. /C.B.// AK2 6,231,613 B1 05-15-2001 Greff, et al. /C.B.// AB3 6,277,39	/C.B./	АН	5,128,326	07-07-1992	Balazs, et al.
/C.B./ AK 5,258,028 11-02-1993 Ersek, et al. /C.B./ AA2 5,306,500 04-26-1994 Rhee, et al. /C.B. AB2 5,336,767 08-09-1994 della Valle, et al. /C.B.//C.B.//AC2 5,399,351 03-21-1995 Leshchiner, et al. /C.B.//AD2 5,523,291 06-04-1996 Janzen, et al. /C.B.//AE2 5,633,001 05-27-1997 Agerup /C.B.//AF2 5,672,301 09-30-1997 Orly, et al. /C.B.//AG2 5,792,478 08-11-1998 Lawin, et al. /C.B.//AH2 5,827,937 10-27-1998 Agerup /C.B.//AH2 6,039,970 03-21-2000 Callegaro, et al. /C.B.//AH2 6,066,340 05-23-2000 Callegaro, et al. /C.B.//AH2 6,231,613 B1 05-15-2001 Greff, et al. /C.B.//AH3 6,251,876 B1 06-26-2001 Bellini, et al. /C.B.//AH3 6,251,876 B1 08-21-2001 Klein /C.B.//AH3 6,288,043 B1 09-11-2001 Spiro, et al.	C.B./	AJ	5,143,724	09-01-1992	Leshchiner, et al.
/C.B./ AA2 5,306,500 04-26-1994 Rhee, et al. /C.B. AB2 5,336,767 08-09-1994 della Valle, et al. /C.B.//C.B.//AC2 5,399,351 03-21-1995 Leshchiner, et al. /C.B.//AD2 5,523,291 06-04-1996 Janzen, et al. /C.B.//AE2 5,633,001 05-27-1997 Agerup /C.B.//AE2 5,672,301 09-30-1997 Orly, et al. /C.B.//AG2 5,792,478 08-11-1998 Lawin, et al. /C.B.//AB2 5,827,937 10-27-1998 Agerup /C.B.//AB2 6,039,970 03-21-2000 Callegaro, et al. /C.B.//AB3 6,231,613 B1 05-15-2001 Greff, et al. /C.B.//AB3 6,251,876 B1 06-26-2001 Bellini, et al. /C.B.//AB3 6,277,392 B1 08-21-2001 Klein /C.B.//AB3 6,288,043 B1 09-11-2001 Spiro, et al.	/C.B./	AJ	5,246,698	09-21-1993	Leshchiner, et al.
IC.B. AB2 5,336,767 08-09-1994 della Valle, et al. IC.B. AC2 5,399,351 03-21-1995 Leshchiner, et al. IC.B. AD2 5,523,291 06-04-1996 Janzen, et al. IC.B. AE2 5,633,001 05-27-1997 Agerup IC.B. AF2 5,672,301 09-30-1997 Orly, et al. IC.B. AG2 5,792,478 08-11-1998 Lawin, et al. IC.B. AH2 5,827,937 10-27-1998 Agerup IC.B. AI2 6,039,970 03-21-2000 Callegaro, et al. IC.B. AI2 6,066,340 05-23-2000 Callegaro, et al. IC.B. AK2 6,231,613 B1 05-15-2001 Greff, et al. IC.B. AA3 6,251,876 B1 06-26-2001 Bellini, et al. IC.B. AC3 6,288,043 B1 09-11-2001 Spiro, et al.	/C.B./	AK	5,258,028	11-02-1993	Ersek, et al.
/C.B. AC2 5,399,351 03-21-1995 Leshchiner, et al. /C.B. AD2 5,523,291 06-04-1996 Janzen, et al. /C.B. AE2 5,633,001 05-27-1997 Ågerup /C.B. AF2 5,672,301 09-30-1997 Orly, et al. /C.B. AG2 5,792,478 08-11-1998 Lawin, et al. /C.B. AH2 5,827,937 10-27-1998 Ågerup /C.B. AI2 6,039,970 03-21-2000 Callegaro, et al. /C.B. AI2 6,066,340 05-23-2000 Callegaro, et al. /C.B. AK2 6,231,613 B1 05-15-2001 Greff, et al. /C.B. AA3 6,251,876 B1 06-26-2001 Bellini, et al. /C.B. AB3 6,277,392 B1 08-21-2001 Klein /C.B. AC3 6,288,043 B1 09-11-2001 Spiro, et al.	/C.B./	AA2	5,306,500	04-26-1994	Rhee, et al.
C.B. AD2 5,523,291 06-04-1996 Janzen, et al. C.B. AE2 5,633,001 05-27-1997 Agerup C.B. AF2 5,672,301 09-30-1997 Orly, et al. C.B. AG2 5,792,478 08-11-1998 Lawin, et al. C.B. AH2 5,827,937 10-27-1998 Agerup C.B. AI2 6,039,970 03-21-2000 Callegaro, et al. C.B. AI2 6,066,340 05-23-2000 Callegaro, et al. C.B. AK2 6,231,613 B1 05-15-2001 Greff, et al. C.B. AA3 6,251,876 B1 06-26-2001 Bellini, et al. C.B. AB3 6,277,392 B1 08-21-2001 Spiro, et al. C.B. AC3 6,288,043 B1 09-11-2001 Spiro, et al. C.B. AC3 6,288,043 B1 09-11-2001 Spiro, et al. C.B. AC3 6,288,043 B1 O9-11-2001 Spiro, et al. C.B. AC3	/C.B.	AB2	5,336,767	08-09-1994	della Valle, et al.
/C.B./AD2 5,523,291 06-04-1996 Janzen, et al. /C.B./AE2 5,633,001 05-27-1997 Ågerup /C.B./AF2 5,672,301 09-30-1997 Orly, et al. /C.B./AG2 5,792,478 08-11-1998 Lawin, et al. /C.B./AH2 5,827,937 10-27-1998 Ågerup /C.B./AI2 6,039,970 03-21-2000 Callegaro, et al. /C.B./AX2 6,231,613 B1 05-15-2001 Greff, et al. /C.B./AX3 6,251,876 B1 06-26-2001 Bellini, et al. /C.B./AB3 6,277,392 B1 08-21-2001 Klein /C.B./AC3 6,288,043 B1 09-11-2001 Spiro, et al.	/C.B.	AC2	5,399,351	03-21-1995	Leshchiner, et al.
/C.B./AE2 5,633,001 05-27-1997 Ågerup /C.B./AF2 5,672,301 09-30-1997 Orly, et al. /C.B./AG2 5,792,478 08-11-1998 Lawin, et al. /C.B./AH2 5,827,937 10-27-1998 Ågerup /C.B./AI2 6,039,970 03-21-2000 Callegaro, et al. /C.B./AI2 6,066,340 05-23-2000 Callegaro, et al. /C.B./AK2 6,231,613 B1 05-15-2001 Greff, et al. /C.B./AA3 6,251,876 B1 06-26-2001 Bellini, et al. /C.B./AB3 6,277,392 B1 08-21-2001 Klein /C.B./AC3 6,288,043 B1 09-11-2001 Spiro, et al.	/C.B./		5,523,291	06-04-1996	Janzen, et al.
/C.B. AF2 5,672,301 09-30-1997 Orly, et al. /C.B. AG2 5,792,478 08-11-1998 Lawin, et al. /C.B. AH2 5,827,937 10-27-1998 Ågerup /C.B. AI2 6,039,970 03-21-2000 Callegaro, et al. /C.B. AJ2 6,066,340 05-23-2000 Callegaro, et al. /C.B. AK2 6,231,613 B1 05-15-2001 Greff, et al. /C.B. AA3 6,251,876 B1 06-26-2001 Bellini, et al. /C.B. AB3 6,277,392 B1 08-21-2001 Klein /C.B. AC3 6,288,043 B1 09-11-2001 Spiro, et al.	/C.B./		5,633,001	05-27-1997	Ågerup
C.B. AG2 5,792,478 08-11-1998 Lawin, et al. C.B. AH2 5,827,937 10-27-1998 Agerup C.B. AI2 6,039,970 03-21-2000 Callegaro, et al. C.B. AI2 6,066,340 05-23-2000 Callegaro, et al. C.B. AK2 6,231,613 B1 05-15-2001 Greff, et al. C.B. AA3 6,251,876 B1 06-26-2001 Bellini, et al. C.B. AB3 6,277,392 B1 08-21-2001 Klein C.B. AC3 6,288,043 B1 09-11-2001 Spiro, et al. C.B. AC3 C.B.	l i	1	5,672,301	09-30-1997	Orly, et al.
/C.B./ AH2 5,827,937 10-27-1998 Ågerup /C.B./ AI2 6,039,970 03-21-2000 Callegaro, et al. /C.B./ AJ2 6,066,340 05-23-2000 Callegaro, et al. /C.B./ AK2 6,231,613 B1 05-15-2001 Greff, et al. /C.B./ AA3 6,251,876 B1 06-26-2001 Bellini, et al. /C.B./ AB3 6,277,392 B1 08-21-2001 Klein /C.B./ AC3 6,288,043 B1 09-11-2001 Spiro, et al.	/C.B./		5,792,478	08-11-1998	Lawin, et al.
/C.B./ A12 6,039,970 03-21-2000 Callegaro, et al. /C.B./ AJ2 6,066,340 05-23-2000 Callegaro, et al. /C.B./ AK2 6,231,613 B1 05-15-2001 Greff, et al. /C.B./ AA3 6,251,876 B1 06-26-2001 Bellini, et al. /C.B./ AB3 6,277,392 B1 08-21-2001 Klein /C.B./ AC3 6,288,043 B1 09-11-2001 Spiro, et al.	1	1 1	5,827,937	10-27-1998	Ågerup
/C.B./ AJ2 6,066,340 05-23-2000 Callegaro, et al. /C.B./ AK2 6,231,613 B1 05-15-2001 Greff, et al. /C.B./ AA3 6,251,876 B1 06-26-2001 Bellini, et al. /C.B./ AB3 6,277,392 B1 08-21-2001 Klein /C.B./ AC3 6,288,043 B1 09-11-2001 Spiro, et al.	/C.B./	i I	6,039,970	03-21-2000	
/C.B./ AK2 6,231,613 B1 05-15-2001 Greff, et al. /C.B./ AA3 6,251,876 B1 06-26-2001 Bellini, et al. /C.B./ AB3 6,277,392 B1 08-21-2001 Klein /C.B./ AC3 6,288,043 B1 09-11-2001 Spiro, et al.	/C.B./	1 1	6,066,340	05-23-2000	Callegaro, et al.
/C.B./ AB3 6,277,392 B1 08-21-2001 Klein /C.B./ AC3 6,288,043 B1 09-11-2001 Spiro, et al.	/C.B./		6,231,613 B1	05-15-2001	Greff, et al.
/C.B./ AC3 6,288,043 B1 09-11-2001 Spiro, et al.	/C.B./	АА3	6,251,876 B1	06-26-2001	Bellini, et al.
IC D	/C.B./	AB3	6,277,392 B1	08-21-2001	Klein
/C.B. AD3 6,418,934 B1 07-16-2002 Chin		 	6,288,043 B1	09-11-2001	Spiro, et al.
	/C.B.	AD3	6,418,934 B1	07-16-2002	Chin

EXAMINER	DATE CONSIDERED
/Courtney Brown/ (09/24/2007)	09/24/2007

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 1767.2011-000		PLICATION NO. /743,557		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Khalid K. Sadozai		FILING DATE December 2	22, 2003	
June 18, 2004 (Use several sheets if necessary)	EXAMINER Not yet assigned	_	CONFIRMATION NO. GROUP 1614		

	U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT				
/C.B./	AE3	6,497,887 B1	12-24-2002	Zecchino, et al.				
/C.B.	AF3	US 2002/0076810 A1	06-20-2002	Radice, et al.				
/C.B./	AG3	US 2003/0060447 A1	03-27-2003	Karakelle, et al.				

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 1767.2011-000	ľ	LICATION NO. 743,557	
[°] INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Khalid K. Sadozai		FILING DATE December 2	22, 2003
June 18, 2004 (Use several sheets if necessary)	EXAMINER Not yet assigned	CONFI 5063	RMATION NO.	GROUP 1614

		F	OREIGN PATENT D	OCUMENTS		
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANS YES	LATION NO
/C.B./	AL	WO 97/04012	02-06-1997	Bengt Ågerup		
/C.B./	AM	EP 0 839 159 B1	08-08-2001	Q MED AB		
/C.B. <i>\</i> ℓ	AN	EP 0 587 106 B1	07-30-1997	Vectorpharma International S.p.A.		
/C.B./	AO	0 341 745 B1	12-14-1994	FIDIA S.p.A.		
/C.B./	AP	EP 0 466 300 B1	05-13-1998	Biomatrix, Inc.		
- /C.B./	AQ	EP 0 655 945 B1	07-01-1998	Coletica		
/C.B./	AL2	JP200239305	09-05-2000	Denki Kagaku Kogyo KK	х	
/C.B./	AM2	EP 0 397 652 B1	06-05-1996	Genzyme Corporation	_	
/C.B./	AN2	WO 9602209A1	02-01-1996	Advanced Uroscience, Inc.		
/C.B./	AO2	EP 0 771 179 B1	08-06-2003	Carbon Medical Technologies, Inc.		
/C.B./	AP2	WO 87/07898	12-30-1987	Pharmacia AB		
/C.B./	AQ2	WO 94/21299	09-29-1994	Medinvent		
/C.B./	AL3	EP 079 446 B1	11-24-1999	FIDIA Advanced Biopolymers S.R.L.		
/C.B./	AM3	EP 0 265 116 B1	03-11-1998	FIDIA S.p.A.		
	AN3					
	AO3					
	AP3					
,	AQ3					
-	AL4					
ı.	AM4					
	AN4					
	AO4					
	AP4					
	AQ4					

EXAMINER	DATE CONSIDERED
/Courtney Brown/ (09/24/2007)	09/24/2007

				Sheet 4 of	
PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 1767.2011-000		APPLICATION NO. 10/743,557		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			FILING DATE December 2	FILING DATE December 22, 2003	
June 18, 2004 (Use several sheets if necessary)	EXAMINER Not yet assigned	CONFIRMATION NO. 5063		GROUP 1614	

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
/C.B./	AR ·	Barbucci, R., et al., "Hyaluronic Acid Hydrogel in the Treatment of Osteoarthritis," Biomaterials 23:4503-4513 (2002).					
C.B./	AS	Milas, M., et al., "Comparative Rheological Behavior of Hyaluronan from Bacterial and Animal Sources with Cross-Linked Hyaluronan (Hylan) in Aqueous Solution," Biopolymers 59:191-204 (2001).					
/C.B./	АТ	Duranti, MD, F., et al., "Injectable Hyaluronic Acid Gel for Soft Tissue Augmentation A Clinical and Histological Study," The American Society for Dermatologic Surgery, Inc., 24:1317-1325 (1998).					
	AU						
	AV						
	AW						
	AX						
	AY						
	AZ						
	AR2						
	AS2						
	AT2						
	AU2						
	AV2						
	AW2						
	AX2						

EXAMINER	DATE CONSIDERED .
/Courtney Brown/ (09/24/2007)	09/24/2007

DT01 Rec'd PCT/PTC _0 4 FEB 2005

			•	·		.,,	T) 4 I FD	
FORM PTO 1449 (modified)				ATTY DOCKET NO. 00005.001205.1 APPLICANT Hiroshi Kase, et al.				
U.S. DEPARTMENT OF COMPS.—CE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)								
(Use several sneets if necessary)					FILING DATE Concurrently herewith	GROUP Not Yet Assigned		
					U.S. PATENT DOCUMENTS			<u> </u>
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
•		5,484,920	1/16/96		Suzuki, et al.	544	268	
		}						
				٠				
						,		
		·		-				
				7				
			<u> </u>	FO	REIGN PATENT DOCUMENTS			,
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION · YES/NO/ OR ABSTRACT
	·		·					
						,		
•		•	OTHER DOCUM	MENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)	•		
							•	

DATE CONSIDERED

Sheet_1_ of _1

EXAMINER

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.